2019
DOI: 10.1098/rsob.190051
|View full text |Cite
|
Sign up to set email alerts
|

Translational control of antibiotic resistance

Abstract: Many antibiotics available in the clinic today directly inhibit bacterial translation. Despite the past success of such drugs, their efficacy is diminishing with the spread of antibiotic resistance. Through the use of ribosomal modifications, ribosomal protection proteins, translation elongation factors and mistranslation, many pathogens are able to establish resistance to common therapeutics. However, current efforts in drug discovery are focused on overcoming these obstacles through the modification or disco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(17 citation statements)
references
References 124 publications
0
17
0
Order By: Relevance
“…Some bacteria are naturally resistant to antibiotics, while others acquire resistance mainly through the misuse of antibiotics and the emergence of new resistant strains [ 24 ]. The mechanism of antibacterial resistance ranges from accelerating antibiotics efflux through bacterial efflux pumps so as to decrease the time required for medication to diffuse inside bacteria [ 25 ], alteration of bacterial porins' structure which decreases bacterial permeability to antibiotic influx [ 26 ], destruction of antibacterial agents by hydrolytic enzymes [ 25 ], to alteration of binding sites for antibiotics [ 27 ]. For bacteria, they may fight antibiotics by one mechanism or by combining more than one to produce their resistance [ 25 ].…”
Section: Mechanism Of Bacterial Resistancementioning
confidence: 99%
“…Some bacteria are naturally resistant to antibiotics, while others acquire resistance mainly through the misuse of antibiotics and the emergence of new resistant strains [ 24 ]. The mechanism of antibacterial resistance ranges from accelerating antibiotics efflux through bacterial efflux pumps so as to decrease the time required for medication to diffuse inside bacteria [ 25 ], alteration of bacterial porins' structure which decreases bacterial permeability to antibiotic influx [ 26 ], destruction of antibacterial agents by hydrolytic enzymes [ 25 ], to alteration of binding sites for antibiotics [ 27 ]. For bacteria, they may fight antibiotics by one mechanism or by combining more than one to produce their resistance [ 25 ].…”
Section: Mechanism Of Bacterial Resistancementioning
confidence: 99%
“…Solithromycin (Solithera) is in phase 3 and expected to have activity against MDR Neisseria gonorrhoeae, and nafithromycin (WCK 4873) is in phase 2. While these new ketolides are not more potent per se than the current ones, they appear not to induce the expression of the corresponding ARE genes to the same degree [23,[76][77][78]. However, these new ketolides are less effective when erm genes are expressed constitutively [78,79].…”
Section: Pharmaceutical Pipeline and Implications For Futurementioning
confidence: 70%
“…Unlike target alteration (AB binding site mutation or modification, e.g., ribosome methylation by specialized methyltransferases), target protection does not involve a permanent change to the target. In case of a target as conserved and functionally fine-tuned as the ribosome, permanent changes that alter the target in order to reduce or abolish AB binding are often accompanied by a fitness cost due to reduced functionality of the highly conserved centers of the ribosome [23]. Hence, there tends to be a trade-off between optimal fitness and ARE.…”
Section: Ribosome Protection Proteinsmentioning
confidence: 99%
See 1 more Smart Citation
“…Spread of antibiotic resistance in bacteria is one of the most urgent issues in medicine, wellknown and long used antibiotics are losing their efficacy over time. The most promising ways to overcome this problem are creating analogs based on existing antibiotics, searching for novel natural substances with antibacterial activity, as well as thorough study of antibacterials and the resistance mechanisms to them (Nicolaou and Rigol, 2018;Witzky et al, 2019). Amicoumacin A (Ami) is a substance with the potential to become a new therapeutic antimicrobial agent.…”
Section: Introductionmentioning
confidence: 99%